0001183740-19-000199.txt : 20190909 0001183740-19-000199.hdr.sgml : 20190909 20190909161031 ACCESSION NUMBER: 0001183740-19-000199 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190909 DATE AS OF CHANGE: 20190909 EFFECTIVENESS DATE: 20190909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SERNOVA CORP. CENTRAL INDEX KEY: 0001491434 IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-348311 FILM NUMBER: 191083179 BUSINESS ADDRESS: STREET 1: 120-700 COLLIP CIRCLE CITY: LONDON STATE: A6 ZIP: N6G 4X8 BUSINESS PHONE: 519-858-5126 MAIL ADDRESS: STREET 1: 120-700 COLLIP CIRCLE CITY: LONDON STATE: A6 ZIP: N6G 4X8 D 1 primary_doc.xml X0708 D LIVE 0001491434 SERNOVA CORP. 700 COLLIP CIRCLE, SUITE 114 LONDON A6 ONTARIO, CANADA N6G 4X8 519-858-5126 CANADA (FEDERAL LEVEL) None None Corporation true Philip Toleikis 700 COLLIP CIRCLE, SUITE 114 LONDON A6 ONTARIO, CANADA N6G 4X8 Executive Officer Director Sean Hodgins 700 COLLIP CIRCLE, SUITE 114 LONDON A6 ONTARIO, CANADA N6G 4X8 Executive Officer Frank A. Holler 700 COLLIP CIRCLE, SUITE 114 LONDON A6 ONTARIO, CANADA N6G 4X8 Director Jeffrey A. Bacha 700 COLLIP CIRCLE, SUITE 114 LONDON A6 ONTARIO, CANADA N6G 4X8 Director James Parsons 700 COLLIP CIRCLE, SUITE 114 LONDON A6 ONTARIO, CANADA N6G 4X8 Director Deborah M. Brown 700 COLLIP CIRCLE, SUITE 114 LONDON A6 ONTARIO, CANADA N6G 4X8 Director Biotechnology Decline to Disclose 06b false 2019-08-30 true true true true true Units comprised of one common share and one common share purchase warrant. Each warrant is exercisable into a common share at C$0.30 per share for 36 months. false 0 250858 100343 150515 Total Offering Amount represents aggregate Unit price (667000xC$0.20(US$0.15)) plus underlying warrant exercise price (667000xC$0.30(US$0.23). No guarantee that warrants, expiring 8/30/2022, will be exercised. Exchange rate of US$1:C$1.3295 on 8/30/2019. false 1 0 0 0 false SERNOVA CORP. /s/ Dr. Philip Toleikis Dr. Philip Toleikis President and CEO 2019-09-06